EMC Capital Management Trims Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

EMC Capital Management trimmed its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 22.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,074 shares of the company’s stock after selling 2,030 shares during the period. EMC Capital Management’s holdings in Prestige Consumer Healthcare were worth $552,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the last quarter. nVerses Capital LLC grew its position in shares of Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares during the last quarter. Huntington National Bank grew its position in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after acquiring an additional 181 shares during the last quarter. International Assets Investment Management LLC increased its holdings in shares of Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after acquiring an additional 1,138 shares during the period. Finally, GAMMA Investing LLC raised its position in Prestige Consumer Healthcare by 49.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock valued at $84,000 after purchasing an additional 387 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on PBH. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $79.11 on Thursday. Prestige Consumer Healthcare Inc. has a 52 week low of $60.00 and a 52 week high of $86.36. The company has a 50-day moving average price of $79.97 and a 200 day moving average price of $75.05. The company has a market cap of $3.91 billion, a P/E ratio of 19.25, a PEG ratio of 2.17 and a beta of 0.51. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period last year, the firm earned $1.07 EPS. The company’s quarterly revenue was down .9% compared to the same quarter last year. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,810 shares of company stock worth $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.